N

North China Pharmaceutical Co Ltd
SSE:600812

Watchlist Manager
North China Pharmaceutical Co Ltd
SSE:600812
Watchlist
Price: 5.62 CNY 0.72% Market Closed
Market Cap: 9.6B CNY

North China Pharmaceutical Co Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

North China Pharmaceutical Co Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
N
North China Pharmaceutical Co Ltd
SSE:600812
Revenue
ÂĄ9.8B
CAGR 3-Years
-1%
CAGR 5-Years
-4%
CAGR 10-Years
3%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Revenue
ÂĄ13.2B
CAGR 3-Years
10%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Revenue
ÂĄ9.8B
CAGR 3-Years
5%
CAGR 5-Years
9%
CAGR 10-Years
19%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Revenue
ÂĄ31B
CAGR 3-Years
13%
CAGR 5-Years
4%
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Revenue
ÂĄ40.8B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
7%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Revenue
ÂĄ5.8B
CAGR 3-Years
94%
CAGR 5-Years
37%
CAGR 10-Years
N/A
No Stocks Found

North China Pharmaceutical Co Ltd
Glance View

Market Cap
9.6B CNY
Industry
Pharmaceuticals

In the heart of China's industrial evolution, North China Pharmaceutical Co., Ltd. (NCPC) has thrived as a prominent player in the global pharmaceutical arena. Established in 1953, NCPC has grown from being a state-owned entity to one of the world's largest antibiotic producers. Nestled within the bustling Shijiazhuang region, the company commands a significant presence in the industry, leveraging its extensive experience and formidable R&D capabilities. The backbone of NCPC's operations lies in its integrated production lines, which link raw materials seamlessly with advanced pharmaceutical synthesis processes. This setup enables the company to efficiently churn out a diverse range of products, from bulk antibiotics like penicillin and streptomycin to high-value biotech and nutritional products. NCPC sustains its financial health through a blend of domestic dominance and robust international outreach, catering to over 100 countries. Its revenue streams are diversified across various segments, including prescription drugs, over-the-counter medication, and nutritional supplements. Central to its business model is the balance between cost-effective mass production and a push towards innovation-driven therapies, aligning with China's broader healthcare reforms. The company's growth is further bolstered by strategic partnerships and continuous improvements in its technological framework, ensuring NCPC remains a key contender in the ever-competitive pharmaceutical landscape. Through these strategies, North China Pharmaceutical not only upholds its legacy but continues to write new chapters in the global pharmaceutical story.

Intrinsic Value
7.01 CNY
Undervaluation 20%
Intrinsic Value
Price
N

See Also

What is North China Pharmaceutical Co Ltd's Revenue?
Revenue
9.8B CNY

Based on the financial report for Sep 30, 2025, North China Pharmaceutical Co Ltd's Revenue amounts to 9.8B CNY.

What is North China Pharmaceutical Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
3%

Over the last year, the Revenue growth was 1%. The average annual Revenue growth rates for North China Pharmaceutical Co Ltd have been -1% over the past three years , -4% over the past five years , and 3% over the past ten years .

Back to Top